Page 1 of 1
A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor
Posted: Mon Apr 18, 2022 5:23 pm
by paul.et1996
Immune checkpoint inhibitors are a relatively new treatment and is already being given in a number of Hospitals worldwide. The natural immune response against cancer cells is enhanced and manipulated with drugs. This immunotherapy is already considered as a first-line treatment for various types of cancer. I personally expect that this new therapy will become the solution for our mpn clones.
This is the first report demonstrating the effectiveness of Pembrolizumab in a MPN patiënt with the JAK2V617F mutation:
https://pubmed.ncbi.nlm.nih.gov/33389657/
Re: A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor
Posted: Wed Apr 20, 2022 3:42 am
by MPN-MATE Admin
Hey Paul...
An interesting Read... Hopefully, works like these will continue to raise hopes for all MPN sufferers into the not too distant futures...
Thanks for Posting buddy...
Best wishes, stay happy, safe & well...
Steve
Re: A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor
Posted: Wed Apr 20, 2022 4:57 am
by Laurenelle5
Hi ,
Very interesting read! Thanks for sharing it.
Linda.
Re: A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor
Posted: Wed Apr 20, 2022 10:16 pm
by paul.et1996
I saw there is already more evidence:
https://ashpublications.org/blood/artic ... JAK2-V617F
(In the Netherlands) the immune checkpointblockade therapy is already being used for a number of cancer types.. This could make it available for MPN more quickly.
Re: A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor
Posted: Thu Apr 21, 2022 12:53 am
by Laurenelle5
Hi
This is so interesting! Thanks again .
Hope for everyone.
Best wishes.
Linda.
